72 results about "Obstructive lung disease" patented technology

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

Embodiments of the disclosure can include biomarkers for systems, methods, and devices for detecting and identifying certain substances, such as chemicals, volatile organic compounds (VOCs), volatile gases (VGs), ketones, cannabis, controlled substances, pharmaceuticals, or anesthetics, in the exhaled breath of a subject or person in real-time; and further diagnosing, treating, and addressing one or more associated health conditions or diseases, including a virus, such as COVID-19, tuberculosis (TB), lung cancer, or chronic obstructive lung disease (COPD).

The invention discloses a multi-electrode ablation device which comprises an electrode assembly, a guiding conduit, a handle and a connector. At least one cavity exists in the guiding conduit. The electrode assembly is arranged at the front end of the guiding conduit and penetrates through the guiding conduit through a line to be connected with the handle, the guiding conduit comprises one or more electrode groups and one or more detection devices, the electrode groups can exert electric energy, radio frequency energy, laser energy, high-density focused ultrasound or low-temperature ablation, and the detection devices are used for detecting temperature, impedance or tension. The handle is connected with the connector and one or more groups of electrode assemblies and comprises one or more control parts, and the control parts are used for controlling shrinkage, opening and energy of the electrode groups and can control the electrode assemblies to stretch out or retreat back to the guiding conduit. The connector is used for providing energy for electrodes. The device can be used for delivering direct current, alternating current and radio frequency energy to foci and can be used for non-medicine treatment of obstructive lung diseases.

The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.

Devices and methods for treating one or more pulmonary diseases while avoiding or minimizing injury to the esophagus and branches of the vagus nerve that run along the outside of the esophagus. The device includes at least one energy delivery element disposed on an elongate member and a means for protecting the esophagus and surrounding tissues, such as esophageal branches of the vagus nerve, during treatment. The energy delivery element is positionable to target at least one nerve in or around the tracheal wall when the elongate member is positioned in the trachea. Energy from the energy delivery element is delivered to the at least one nerve to treat pulmonary symptoms, conditions, and/or diseases, such as asthma, COPD, obstructive lung diseases, or other pulmonary diseases, while the protection means protects the esophagus and surrounding tissues from permanent damage.

The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.

The compound Chinese onion preparation for treating chronic obstructive lung disease is prepared with Chinese onion, trichosanthes peel, Chinese goldthread, immature bitter orange, cassia twig and other chinese medicine materials. The preparation process includes crushing material, ethanol extraction, depression recovery of ethanol, concentration, adding supplementary material, vacuum drying to obtain dry extract, crushing, and further steps to prepare tablet, capsule, drip pills and micro pills. The compound Chinese onion preparation has obvious functions of relieving cough, eliminating phlegm and relieving asthma, and may be used to treat chronic obstructive lung disease effectively. It is ideal medicine for COPD in acute stage and COPD in prolonged stage and chronic stage.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an antihistamine for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The invention relates to a preparation method and an application of a Magnolia flower volatile oil soft capsule for treating allergic rhinitis and associated diseases. The Magnolia flower volatile oil soft capsule contains the following ingredients in parts by volume: 1 to 90 parts of Magnolia flower volatile oil, 10 to 90 parts of oil phase, 0 to 50 parts of emulsifier and 0 to 30 of co-solvent. The Magnolia flower volatile oil soft capsule, provided by the invention, is also available in the form of an enteric-coated soft capsule, so as to reduce irritation to the stomach and enhance the patient compliance. The soft capsule provided by the invention is used for treating allergic rhinitis, acute rhinitis, simple rhinitis, hypertrophic rhinitis, atrophic rhinitis, acute nasosinusitis, chronic nasosinusitis or complications thereof, as well as respiratory diseases such as acute upper respiratory infection, acute/chronic obstructive lung disease and asthma, with remarkable curative effects.

The present invention relates to procaterol preparation, and especially one new kind of procaterol dripping pill for treating bronchial asthma, asthma bronchitis and chronic obstructive lung diseases and its preparation process. The medicine releasing rate of procaterol may be regulated via selecting different dripping pill matrix, composition and coating material. The preparation may contain stabilizer and corrective, the dripping pill may have or have no coating, and the dripping pill may be held under tongue or orally taken with completely dissolving and dispersing time of 1-15 min. The present invention has simple preparation process, controllable quality, high stability and convenient use.

The invention provides an atomizing agent for treating the chronic obstructive pulmonary disease. The atomizing agent at least comprises at least one of choline, gentiopicroside, peimine, berberine and glycyrrhetinic acid. Research in the invention finds that active ingredients cooperate with each other, and the synergistic active ingredients are locally administrated in respiratory tracts and lungs through an atomization means, so that the effects of cleaning the airway, humidifying the airway, reducing infiltration of inflammatory cells, inhibiting release of interleukin and other cytokines,improving airway stenosis and remarkably improving the treatment effect can be achieved; moreover, the cell intolerance of local administration can be synergistically reduced; and the cytotoxicity can be remarkably reduced.

The invention provides a toxin-eliminating drug composition, a drug preparation and preparation methods of the drug composition and the drug preparation. The drug composition comprises the following components in parts by weight: 7-10 parts of dogbane, 15-18 parts of field sowthistle herb, 15-18 parts of dandelions and 3-5 parts of ginger, wherein dogbane has the functions of calming the liver, clearing heat, improving the eyesight and reducing internal heat and blood pressure; under the action of the drug dogbane, the content of nicotine in human bodies is reduced to some extent, thus reducing the harms of nicotine to human bodies; field sowthistle herb has the function of eliminating the toxicity of nicotine; the dandelions and ginger can be used for promoting the release of nicotine from the bodies and preventing and relieving such diseases caused by smoking as bronchitis, lung cancers, chronic obstructive lung diseases, atherosclerosis lesions and duodenal ulcer of smokers; therefore under the synergistic action of dogbane, field sowthistle herb, dandelions and ginger, the toxin-eliminating drug composition and drug preparation provided by the invention can be used for reducing the harms of nicotine to human bodies.

The invention discloses a whole-lung forced oscillation spectrum detection system composed of a vibration generator and an infrasound sensor which are mutually matched in use. The vibration generator is connected with an oral airway interface through a connecting pipe. The infrasound sensor is provided with a chest strap binding the chest of a patient. The whole-lung forced oscillation spectrum detection system further comprises a computer which is connected with the infrasound sensor. By the detection system which is taken as a supplement to lung functional test, diseases of chronic obstructive lung disease, asthma and the like can be more sensitively diagnosed, and detection performed in calm breathing with no need for cooperation of the patient can reflect the situation of the lung function of the patient, at different parts. The whole-lung forced oscillation spectrum detection system can be used for identifying respiratory diseases of the chronic obstructive lung disease and the asthma, evaluating the effect of the treatment, detecting early tumors and the like.

The invention provides a medical application of spearmint oil in preparation of medicaments for treating chronic obstructive pulmonary diseases. The spearmint is taken from labiatae mentha, is obtained by vapor distillation and rectification, and mainly contains 20-60% of limonene and 20-70% of carvone. The pharmacodynamics proves that the spearmint oil provided by the invention lowers the contents of lung tissue TNF (tumor necrosis factor)-alpha and IL-1 beta for lipopolysaccharide, inhibits the over-expression of MMP-9, has an effect on improving models of Klebsiella pneumoniae infection and rat chronic obstructive pulmonary diseases caused by LPS (lipopolysaccharide), has an effect on reducing expression enhancement of lung tissue Nrf2 protein of a COPD (chronic obstructive pulmonary disease) model, and lowers the content of lung tissue IL-8 and the expression of a CCR2 receptor. The spearmint oil provided by the invention is natural and nontoxic and can be used for preparing medicaments for treating chronic obstructive pulmonary diseases.

The invention discloses a traditional Chinese medicine auxiliary diagnosis and treatment method and system for a chronic obstructive pulmonary disease. The method comprises the steps: collecting symptom information of a patient with the chronic obstructive pulmonary disease; preprocessing the symptom information to obtain a traditional Chinese medicine symptom type result corresponding to the symptom feature vector; according to the traditional Chinese medicine syndrome type result, acquiring recommended drugs through judgment; then performing, by the user, corresponding intervention correction according to the traditional Chinese medicine syndrome type result and the recommended medicine; and recording the treatment process of the chronic obstructive pulmonary disease patient and ending the treatment. According to the method provided by the invention, the traditional Chinese medicine auxiliary diagnosis and treatment process of the chronic obstructive pulmonary disease is decomposed into two links of syndrome type judgment and drug recommendation, and the relevance among symptoms, syndrome types and drugs in a traditional Chinese medicine diagnosis and treatment data set of the chronic obstructive pulmonary disease is fully utilized in the construction process of the syndrome type judgment model and the drug recommendation model. Therefore, the auxiliary diagnosis and treatment information with a relatively good auxiliary effect is obtained.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The invention relates to the technical field of lung disease treatment, in particular to application of stem cell-derived exosomes in preparation of drugs for treating chronic obstructive pulmonary diseases. The research shows that the exosome which is small in structure and can be more easily taken by recipient cells has a treatment effect similar to that of stem cells in treatment of chronic obstructive pulmonary diseases, and is more easily taken by the recipient cells due to no immunological rejection, so that the exosome can be used as a substitute of the stem cells and can be used for treating chronic obstructive pulmonary diseases. A new thought and strategy are provided for treating the chronic obstructive pulmonary disease.

The invention discloses a novel application of naringin in preparation of a medicine for treating chronic obstructive pulmonary disease. In particular to application of naringin in preparation of drugs for treating chronic obstructive pulmonary diseases induced by diesel PM2.5 particles, including preparation of drugs for treating lung tissue elastic resistance reduction, lung tissue airway resistance increase or lung tracheal wall or alveolar cavity thickening induced by diesel PM2.5 particles. Tests prove that the naringin can be used as a medicinal active component and can be matched with a pharmaceutically acceptable carrier, so that a basis is provided for preventing and treating the chronic obstructive pulmonary disease, and the life quality of a patient is improved.

The present invention relates to methods of diagnosing and/or determining a prognosis for various diseases, including lung diseases such as idiopathic pulmonary fibrosis, chronic obstructive lung disease, and emphysema as well as osteoporosis, comprising detecting the presence of autoantibodies specific for heat shock proteins in a subject.

The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound. The compound of the invention can be useful in the treatmentof a disease state selected from: atherosclerosis, disorders related to vasogenic edema, postsurgical abdominal edema, ocular edema, cerebral edema, local and systemic edema, fluid retention, sepsis,hypertension, inflammation, bone related dysfunctions and congestive heart failure, pulmonary disorders, chronic obstructive pulmonary disorder, ventilator induced lung injury, high altitude inducedpulmonary edema, acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, sinusitis/rhinitis, asthma, cough; including acute cough, sub-acute cough and chronic cough, pulmonary hypertension, overactive bladder, cystitis, pain, motor neuron disorders, genetic gain of function disorders, cardiovascular disease, renal dysfunction, stroke, glaucoma, retinopathy, endometriosis, pre-term labor, dermatitis, pruritus, pruritus in liver disease, diabetes, metabolic disorder, obesity, migraine, pancreatitis, tumor suppression, immunosuppression, osteoarthritis, crohn's disease, colitis, diarrhea, intestinal irregularity (hyperreactivity/hyporeactivity), fecal incontinence, irritable bowel syndrome (IBS), constipation, intestinal pain and cramping, celiac disease, lactose intolerance, and flatulence.